11 Results for "

E-CDK2

" in MedChemExpress (MCE) Product Catalog:
Products (11)

11 Results for "E-CDK2" in MCE Product Catalog:

  • Categories Recommended:
    More
7
7 Publications Verification
Cat. No.: HY-10424
CAS No.: 802539-81-7
Purity:  99.90%
Synonyms: PHA-848125
Target:  

CDK Autophagy

Research Areas:  

Cancer

Milciclib (PHA-848125) is a potent, ATP-competitive and dual inhibitor of CDK and Tropomyosin receptor kinase (TRK), with IC50s of 45, 150, 160, 363, 398 nM and 53 nM for cyclin A/CDK2, cyclin H/CDK7, cyclin D1/CDK4, cyclin E/CDK2, cyclin B/CDK1 and TRKA, respectively.
loading...
    loading...
7
7 Publications Verification
Cat. No.: HY-11009
CAS No.: 164658-13-3
Purity:  98.90%
Target:  

CDK PKC

Research Areas:  

Cancer

CGP60474, a highly potent anti-endotoxemic agent, is a potent cyclin-dependent kinase (CDK) inhibitor (IC50 values are 26, 3, 4, 216, 10, 200 and 13 nM for CDK1/B, CDK2/E, CDK2/A, CDK4/D, CDK5/p25, CDK7/H and CDK9/T, respectively). CGP60474 is a selective and ATP-competitive PKC inhibitor [2] .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-15504A
CAS No.: 784210-88-4
Purity:  98.02%
Target:  

CDK GSK-3 MEK JAK Apoptosis JNK

RGB-286638 free base is a potent inhibitor of CDK and MAPK9. RGB-286638 free base inhibits the activities of cyclin T1-CDK9, cyclin B1-CDK1, cyclin E-CDK2, cyclin D1-CDK4, cyclin E-CDK3 and p35-CDK5, with IC50 values of 1, 2, 3, 4, 5 and 5 nM, respectively. RGB-286638 free base inhibits GSK-3β and TAK1, with IC50 values of 3 nM and 5 nM, respectively. RGB-286638 free base induces caspase-dependent Apoptosis in cells. RGB-286638 free base delays tumor growth in an orthotopic glioblastoma mouse model. RGB-286638 free base extends survival in multiple myeloma models. RGB-286638 free base can be used in research related to glioblastoma and multiple myeloma [2].
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-15504
CAS No.: 784210-87-3
Purity:  99.70%
Target:  

CDK GSK-3 MEK JAK Apoptosis JNK

Research Areas:  

Neurological Disease Cancer

RGB-286638 is a potent inhibitor of CDK and MAPK9. RGB-286638 inhibits the activities of cyclin T1-CDK9, cyclin B1-CDK1, cyclin E-CDK2, cyclin D1-CDK4, cyclin E-CDK3 and p35-CDK5, with IC50 values of 1, 2, 3, 4, 5 and 5 nM, respectively. RGB-286638 inhibits GSK-3β and TAK1, with IC50 values of 3 nM and 5 nM, respectively. RGB-286638 induces caspase-dependent Apoptosis in cells. RGB-286638 delays tumor growth in an orthotopic glioblastoma mouse model. RGB-286638 extends survival in multiple myeloma models. RGB-286638 can be used in research related to glioblastoma and multiple myeloma [2].
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-112158
CAS No.: 1147-56-4
Purity:  99.86%
Synonyms: ERGi-USU
Target:  

RIO Kinase

Research Areas:  

Cancer

NSC139021 (ERGi-USU) is a RIOK2 inhibitor with anticancer activity. RIOK2 can highly selectively inhibit the growth of ERG-positive cancer cells with IC50s of 30-400 nM against cell lines. RIOK2 also causes cell cycle arrest and apoptosis in glioblastoma via induction of Skp2 and Skp2-p27/p21-Cyclin E/CDK2-pRb signaling [2].
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-12843
CAS No.: 189232-42-6
Purity:  98.93%
Target:  

CDK ERK

Research Areas:  

Cancer

Bohemine is a purine analogue and is a synthetic and selective CDK inhibitor with IC50s of 4.6 μM, 83 μM, and 2.7 μM for Cdk2/cyclin E, Cdk2/cyclin A, and Cdk9/cyclin T1, respectively. Bohemine also inhibits ERK2 with an IC50 of 52 μM and has less inhibitory effect on CDK1, CDK4 and CDK6. Bohemine has a broad spectrum anti-cancer activities [2].
loading...
    loading...
Cat. No.: HY-112371
CAS No.: 1084893-56-0
Purity:  ≥99.0%
Target:  

CDK

Research Areas:  

Cancer

(S)-CR8 is the S-isomer of CR8. (S)-CR8 is a potent and selective CDK inhibitor with IC50s of 0.060, 0.080, 0.11, 0.12, and 0.15 μM for CDK2/cyclin E, CDK2/cyclin A, CDK9/cyclin T, CDK5/p25, and CDK1/cyclin B, respectively. (S)-CR8 reduces SH-SY5Y cells survival (IC50 0.40 μM) .
loading...
    loading...
Cat. No.: HY-153221
CAS No.: 2845096-18-4
Target:  

CDK

Research Areas:  

Cancer

QR-6401 is an orally active and selective macrocyclic CDK2 inhibitor with IC50 values of 0.37, 10, 22, 34 and 45 nM for CDK2/E1, CDK9/T1, CDK1/A2, CDK6/D3 and CDK4/D1, respectively. QR-6401 has potent antitumor activity in an OVCAR3 ovarian cancer xenograft model. QR-6401 has the potential to be used in the study of cancer .
loading...
    loading...
Cat. No.: HY-P10324
Synonyms: p16INK4a peptide
Target:  

Inhibitory Antibodies

Research Areas:  

Cancer

TAT-p16 (p16INK4a peptide) is a peptide mimic of p16INK4a that can induce an early G phase cell cycle arrest in the absence of active cyclin E:Cdk2 complex .
loading...
    loading...
Cat. No.: HY-10424R
CAS No.: 802539-81-7
Synonyms: PHA-848125 (Standard)
Research Areas:  

Cancer

Milciclib (Standard) is the analytical standard of Milciclib. This product is intended for research and analytical applications. Milciclib (PHA-848125) is a potent, ATP-competitive and dual inhibitor of CDK and Tropomyosin receptor kinase (TRK), with IC50s of 45, 150, 160, 363, 398 nM and 53 nM for cyclin A/CDK2, cyclin H/CDK7, cyclin D1/CDK4, cyclin E/CDK2, cyclin B/CDK1 and TRKA, respectively.
loading...
    loading...
Cat. No.: HY-11009R
CAS No.: 164658-13-3
Research Areas:  

Cancer

CGP60474 (Standard) is the analytical standard of CGP60474 (HY-11009). This product is intended for research and analytical applications. CGP60474, a highly potent anti-endotoxemic agent, is a potent cyclin-dependent Kinase (CDK) inhibitor (IC50 values are 26, 3, 4, 216, 10, 200 and 13 nM for CDK1/B, CDK2/E, CDK2/A, CDK4/D, CDK5/p25, CDK7/H and CDK9/T, respectively). CGP60474 is a selective and ATP-competitive PKC inhibitor [2] .
loading...
    loading...
  • 1